Nichols & Pratt Advisers LLP MA Has $18.11 Million Stake in Stryker Co. (NYSE:SYK)

Nichols & Pratt Advisers LLP MA lowered its position in shares of Stryker Co. (NYSE:SYK) by 0.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 50,303 shares of the medical technology company’s stock after selling 170 shares during the quarter. Stryker accounts for approximately 1.2% of Nichols & Pratt Advisers LLP MA’s investment portfolio, making the stock its 26th biggest holding. Nichols & Pratt Advisers LLP MA’s holdings in Stryker were worth $18,112,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of SYK. Dunhill Financial LLC raised its holdings in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares during the period. Centricity Wealth Management LLC purchased a new position in shares of Stryker during the 4th quarter valued at $30,000. BankPlus Trust Department purchased a new position in shares of Stryker during the 4th quarter valued at $33,000. Darwin Wealth Management LLC purchased a new position in shares of Stryker during the 3rd quarter valued at $36,000. Finally, Activest Wealth Management purchased a new position in shares of Stryker during the 4th quarter valued at $36,000. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of several research reports. Argus set a $450.00 target price on shares of Stryker in a research report on Monday, February 3rd. Canaccord Genuity Group upped their target price on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Barclays upped their target price on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. boosted their price target on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

Stryker Stock Performance

Stryker stock opened at $386.55 on Friday. The company’s 50-day moving average price is $380.50 and its 200-day moving average price is $370.92. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a market cap of $147.50 billion, a PE ratio of 49.81, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business posted $3.46 EPS. On average, equities research analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. Stryker’s payout ratio is 43.30%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.